Toward clinical trials of DNA vaccines against malaria

Immunology and Cell Biology

Volumn 75, Issue 4, 1997, Pages 376-381

  Hoffman, Stephen L ^a   Doolan, Denise L ^a,b   Sedegah, Martha ^a,c   Wang, Ruobing ^a,d   Scheller, Libia F ^a   Kumar, Anita ^a,d   Weiss, Walter R ^a   Le, Thong P ^a   Klinman, Dennis M ^e   Hobart, Peter ^f   Norman, Jon A ^f   Hedstrom, Richard C ^a  

^a NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^b PAN AMERICAN HEALTH ORGANIZATION   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f VICAL INC   (United States)

Author keywords

DNA vaccine; Malaria; Plasmodium; Protective immunity

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; MALARIA VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; REVIEW; T LYMPHOCYTE;

PLASMODIUM FALCIPARUM;

EID: 9844265394     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.59     Document Type: Review

References (65)

1. Hoffman SL, Miller LH. Perspectives on malaria vaccine development. In: Hoffman SL (ed.) Malaria Vaccine Development. Washington DC: ASM Press, 1996; 1-14.
2. Doolan DL, Hoffman SL. Multi-gene vaccination against malaria: a multi-stage, multi-immune response approach. Parasitol. Today 1997; 13: 171-8.
3. Nussenzweig RS, Vanderberg J, Most H, Orton C. Specificity of protective immunity produced by X-irradiated Plasmodium berghei sporozoites. Nature 1969; 222: 488-9.
4. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull. World Health Organ. 1979; 57: 165-73.
5. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973; 266: 398-401.
6. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973; 266: 169-77.
7. Clyde DF, McCarthy VC, Miller RM, Woodward WE. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 1975; 24: 397-401.
8. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 1974; 68: 258-9.
9. Herrington D, Davis J, Nardin E et al. Successful immunization of humans with irradiated sporozoites: humoral and cellular responses of the protected individuals. Am. J. Trop. Med. Hyg. 1991; 45: 539-47.
10. Rieckmann KH, Beaudoin RL, Cassells JS, Sell DW. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull. World Health Organ. 1979; 57: 261-5.
11. Egan JE, Hoffman SL, Haynes JD et al. Humoral immune response in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 1993; 49: 166-73.
12. Edelman R, Hoffman SL, Davis JR et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J. Infect. Dis. 1993; 168: 1066-70.
13. Hoffman SL, Franke ED, Hollingdale MR, Druilhe P. Attacking the infected hepatocyte. In: Hoffman SL (ed.) Malaria Vaccine Development. Washington DC: ASM Press, 1996; 35-76.
14. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987; 330: 664-6.
15. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl Acad. Sci. USA 1988; 85: 573-6.
16. + T cells. J. Exp. Med. 1994; 180: 353-8.
17. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989; 341: 323-5.
18. + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Imunol. 1991; 3: 579-85.
19. Weiss WR, Berzovsky JA, Houghten R, Sedegah M, Hollingdale M, Hoffman SL. A T cell clone directed at the circumsporozoite protein which protects mice against both P. yoelii and P. berghei. J. Immunol. 1992; 149: 2103-9.
20. + cytotoxic T cell clone recognizing sporozoite surface protein 2. Infect. Immun. 1994; 62: 2979-83.
21. Ferreira A, Schofield L, Enea V et al. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 1986; 232: 881-4.
22. Maheshwari RK, Czarniecki CW, Dutta GP, Puri SK, Dhawan BN, Friedman RM. Recombinant human gamma interferon inhibits simian malaria. Infect. Immun. 1986; 53: 628-30.
23. Sedegah M, Finkelman F, Hoffman SL. Interleukin-12 induction of interferon-gamma-dependent protection against malaria. Proc. Natl Acad. Sci. USA 1994; 91: 10 700-2.
24. Hoffman SL, Crutcher JM, Puri SK et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nature Med. 1997; 3: 80-3.
25. Hoffman SL, Weiss W, Mellouk S, Sedegah M. Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunol. Lett. 1990; 25: 33-8.
26. Hoffman SL, Isenbarger D, Long GW et al. T lymphocytes from mice immunized with irradiated sporozoites eliminate malaria from hepatocytes. Bull. World Health Organ. 1990; 68: 132-7.
27. Weiss WR, Mellouk S, Houghten RA et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J. Exp. Med. 1990; 171: 763-73.
28. Mellouk S, Maheshwari RK, Rhodes-Feuillette A et al. Inhibitory activity of interferons and interleukin-1 on the development of Plasmodium falciparum in human hepatocyte cultures. J. Immunol. 1987; 139: 4192-5.
29. Mellouk S, Green SJ, Nacy CA, Hoffman SL. IFN-gamma inhibits development of Plasmadium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J. Immunol. 1991; 146: 3971-6.
30. Mellouk S, Hoffman SL, Liu ZZ, De la Vega P, Billiar TR, Nussler AK. Nitric oxide-mediated anti-plasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. Infect. Immun. 1994; 62: 4043-6.
31. Sadoff JC, Ballou WR, Baron LS et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988; 240: 336-8.
32. + cytotoxic T cells. J. Exp. Med. 1991; 172: 1083-90.
33. Lanar DE, Tine JA, de Taisne C et al. Attenuated vaccinia virus recombinants confer protection against rodent malaria. Infect. Immun. 1996; 64: 1666-71.
34. Sedegah M, Beaudoin RL, De la Vega P et al. Use of a vaccinia construct expressing the circumsporozoite protein in the analysis of protective immunity to Plasmodium yoelii. In: Lasky L (ed.) Technological Advances in Vaccine Development. New York: Liss, 1988; 295-309.
35. Sedegah M, Beaudoin RL, Majarian WR et al. Evaluation of vaccines designed to induce protective cellular immunity against the Plasmodium yoelii circumsporozoite protein: vaccinia, pseudorabies, and salmonella transformed with circumsporozoite gene. Bull. World Health Organ. 1990; 68: 109-14.
36. Sedegah M, Chiang CH, Weiss WR et al. Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity. Vaccine 1992; 10: 578-84.
37. + T-cell-mediated protective immunity against malaria. Proc. Natl Acad. Sci. USA 1993; 90: 5214-18.
38. Khusmith S, Charoenvit Y, Kumar S, Sedegah M, Beaudoin RL, Hoffman SL. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991; 252: 715-18.
39. Gonzalez C, Hone D, Noriega FR et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 1994; 169: 927-31.
40. Tine JA, Lanar DE, Smith DM et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 1996; 64: 3833-44.
41. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl Acad. Sci. USA 1994; 91: 9866-70.
42. + T cell, interferon-γ, and nitric oxide dependent immunity. J. Exp. Med. 1996; 183: 1739-46.
43. Charoenvit Y, Mellouk S, Sedegah M et al. 17 kDa Plasmodium yoelii hepatic and erythrocytic stage protein is the target of protective antibodies. Exp. Parasitol. 1995; 80: 419-29.
44. Doolan DL, Hedstrom RC, Rogers WO et al. Characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii: homolog of P. falciparum exported protein-1. J. Biol. Chem. 1996; 271: 17 861-8.
45. Williams RS, Johnston SA, Riedy M, DeVit MJ, McElligot SG, Sanford JC. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc. Natl Acad. Sci. USA 1991; 88: 2726-30.
46. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-4.
47. Raz E, Carson DA, Parker SE et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc. Natl Acad. Sci. USA 1994; 91: 9519-23.
48. Rogers WO, Malik A, Mellouk S et al. Characterization of Plasmodium falciparum, sporozoite surface protein 2. Proc. Natl Acad. Sci. USA 1992; 89: 9176-80.
49. Malik A, Egan JE, Houghten RA, Sadoff JC, Hoffman SL. Human cytotoxic T lymphocytes against Plasmodium falciparum circumsporozoite protein. Proc. Natl Acad. Sci. USA 1991; 88: 3300-4.
50. Wizel B, Houghten R, Church P et al. HLA-A2 restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite protein 2 epitopes in sporozoite-immunized volunteers. J. Immunol. 1995; 155: 766-75.
51. Wizel B, Houghten RA, Parker KC et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J. Exp. Med. 1995; 182: 1435-45.
52. Doolan DL, Houghten RA, Good MF. Location of human cytotoxic T cell epitopes within a polymorphic domain of the Plasmodium falciparum circumsporozoite protein. Int. Immunol. 1991; 3: 511-16.
53. + cytotoxic T-lymphocytes against the Plasmodium falciparum circumsporozoite protein. J. Immunol. 1992; 149: 966-71.
54. Hill AVS, Elvin J, Willis AC et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360: 434-9.
55. Aidoo M, Lalvani MRCP, Allsopp CEM et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet. 1995; 345: 1003-7.
56. Doolan DL, Hoffman SL, Southwood S et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and -B supertype alleles. Immunity 1997 (in press).
57. Hartikka J, Sawdey M, Comefert-Jensen F et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther. 1996; 7: 1205-17.
58. Luke CJ, Carner K, Liang X, Barbour AG. An OspA-based DNA vaccine protects mice against infection with Borrelai burgdorferi. J. Infect. Dis. 1997; 175: 91-7.
59. Mor G, Singla M, Steinberg AD, Hoffman SL, Okuda K, Klinman DM. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 1997; 8: 293-300.
60. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into the host genome. Ann. N.Y. Acad. Sci. 1995; 772: 30-9.
61. Church LWP, Le TP, Bryan JP et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J. Infect. Dis. 1997; 175: 915-20.
62. Hoffman SL. Experimental challenge of volunteers with malaria. Ann. Intern. Med. 1997; (in press).
63. Hoffman SL (ed.) Malaria Vaccine Development. Washington DC: ASM Press, 1996; 1-227.
64. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vacine against Plasmodium falciparum malaria. N. Eng. J. Med. 1997; 336: 86-91.
65. Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, National Research Council. Washington DC: National Academy Press, 1996.